Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS-COV-2

Osivax's novel oligoDOM® technology, designed to induce potent T-cell responses, will serve as the basis for this broad-spectrum vaccine against COVID-19

Osivax, a French biotechnology company pioneering a new class of universal vaccines against ever-mutating viruses thanks to its patented oligoDOM® technology, and CDMO 3P Biopharmaceuticals are collaborating on the development of a broad-spectrum vaccine against COVID-19. 3P’s role will focus on process scale-up and cGMP production of Osivax’s vaccine for use in Phase I clinical trials.

Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS-COV-2

The benefit of this vaccine compared to others lies mainly in the fact that it targets a part of the virus that is much less prone to mutation: the nucleocapsid. Osivax oligoDOM® (OVX313) technology enables the transformation of the nucleocapsid into a highly immunogenic antigen to trigger potent B- and T-cell immune responses.

Current research efforts are mostly directed towards Spike, an antigen on the surface of the coronavirus, which have shown to vary from variant to variant. By targeting the nucleocapsid, an internal antigen that is much less prone to mutation, Osivax’s vaccine would provide a universal approach to combat all current and future SARS-COV-2 variants.

Dámaso Molero, CEO of 3P Biopharmaceuticals said: “To be able to say that we are collaborating with Osivax on such a novel and important technology platform such as oligoDOM® to help prevent pandemics like COVID-19, is a real achievement for 3P“.

This collaboration is also a step forward for Osivax in fulfilling its mission to pioneer a new class of universal vaccine: Alexandre Le Vert, CEO of Osivax, stated, “The development of our pan-coronavirus vaccine will provide additional evidence on the relevance of our universal vaccination approach and the potential of oligoDOM® vaccines to revolutionize the prevention of ever-evolving global infectious diseases.

View the full press release here

Our dedicated team of specialists will be happy to discuss any of your CDMO supply chain needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals is moving forward with its expansion plan and the adaptation of its facilities.

Published: 9th March 2023
The biotechnology company from Navarra opens its third installation in Noáin.
Read more

3P Biopharmaceuticals increases its microbial production capacity with the installation of a 500 L fermenter.

Published: 1st March 2023
The fermenter adds to 3P's capacity for manufacturing biological medicinal products using microbial technology.
Read more

3P Biopharmaceuticals has a 68% female workforce with a scientific background.

Published: 10th February 2023
On the occasion of the International Day of Women and Girls in Science, the company presents 5 stories of science in feminine.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.